OSLO,
Norway, May 26, 2023 /PRNewswire/
-- Following the closing of the acceptance period in the
previously announced public offer, Navamedic ASA (OSE: NAVA), a
Nordic pharma company and reliable provider of high-quality
products to hospitals and pharmacies, will become the owner of
96.33 per cent of the share capital and votes and 93.16 per cent of
the series TO 1 warrants ("Warrants") in Sensidose Aktiebolag
("Sensidose).
This is an important milestone in Navamedic's plan to acquire
all outstanding shares and include Sensidose's product offering in
its well proven and highly scalable market access platform for
healthcare products. Navamedic now plans to initiate a compulsory
acquisition of the remaining shares in Sensidose, and to promote a
delisting of the Sensidose shares and Warrants from the Spotlight
Stock Market in Sweden.
"We are excited by the prospect of becoming the owner of
Sensidose. Our next step will be to add Sensidose's unique
Parkinson's treatment to our existing marketing and distribution
channels and rapidly ramp up commercialisation efforts in the
Nordics.
We have previously proven our ability to quickly improve product
sales through our agile platform and know-how in the markets where
we operate and have already mapped out several opportunities to
increase the sales of Sensidose's treatment in some of our core
markets.
Moving forward, we look forward to cooperating closely with
Sensidose and its highly skilled team to ensure long-term success,"
said Kathrine Gamborg Andreassen,
CEO of Navamedic.
As of the end of the acceptance period, 25 May 2023, shareholders owning 4,715,283 shares
and 1,560,445 Warrants had tendered their shares and Warrants,
corresponding to approximately 39.43 per cent of the share capital
and votes and approximately 68.89 per cent of the Warrants in
Sensidose respectively. Navamedic already holds 56.90 per cent of
the outstanding shares and 24.27 per cent of the Warrants in the
company.
The settlement of the shares and Warrants tendered in the offer
is expected to commence on or around 1 June
2023.
Sensidose is a Sweden-based
pharmaceutical company that sells drugs in combination with an
innovative device for individual dosing for patients with advanced
Parkinson's disease. Approximately 270 patients are being treated
with Sensidose's medicine in Sweden, Norway and Denmark. Sensidose has already received market
approval in market approval in eight additional countries,
including Finland, whereby the
company has been granted reimbursement.
For further information, please
contact:
Kathrine Gamborg
Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
About Navamedic ASA
Navamedic ASA is a Nordic pharma company and reliable
provider of high-quality products, delivered to hospitals and
through pharmacies, meeting the specific needs of patients and
consumers by leveraging its highly scalable market access platform,
leading category competence and local knowledge. Navamedic is
present in all the Nordic countries, the Baltics and Benelux, with
sales representation in the UK and Greece. Navamedic is headquartered in
Oslo, Norway, and listed on the
Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com
This information is considered to be inside information
pursuant to the EU Market Abuse Regulation (MAR) and is subject to
the disclosure requirements pursuant to Section 5-12 the Norwegian
Securities Trading Act. The information was submitted for
publication by CFO Lars Hjarrand on
26 May 2023 at 08.00 (CEST).
View original
content:https://www.prnewswire.co.uk/news-releases/navamedic-to-own-a-total-of-96-33-per-cent-of-shares-in-sensidose-following-closing-of-public-offer-301835421.html